大中国区摘要
Region China Abstract

● 诺和诺德在整体胰岛素市场的销量市场份额达到48.5%。胰岛素集中带量采购已于2022年5月实施，受其影响，大中国区胰岛素销售额以丹麦克朗计算下降16%。同时，由诺和佳^®和诺和益^®带来的增长，部分抵消了相关影响。

● Novo Nordisk has a volume market share of 48.5% of the total insulin market. Sales of insulin in Region China decreased by 16% measured in Danish kroner due to the implementation of Volume Based Procurement from May 2022. Meanwhile, the sales decline was partially countered by Ryzodeg^® and Xulthopy^®.

● 大中国区2型糖尿病治疗领域GLP-1产品销售以丹麦克朗计算增长102%，反映出诺和泰^®的强劲增长。诺和泰^®已被纳入国家医保目录报销体系。新版国家医保药品目录已于2022年1月1日起正式实施。

● GLP-1 sales in Region China increased by 102% measured in Danish kroner. The sales growth reflects the uptake of Ozempic^®. Ozempic^® has been included on the National Reimbursement List in China. The new version of the National Reimbursement List in China has been implemented as of 1 January 2022.

● 大中国区罕见病领域销售增长101%。

● Rare disease sales in Region China increased by 101%.

财报摘要
Financial Report Abstract

● 经营利润以丹麦克朗计算增长28%，以固定汇率（CER）计算增长15%，至748亿丹麦克朗。

● Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. 

● 北美运营部销售以丹麦克朗计算增长35%（以CER计算增长21%），国际运营部销售以丹麦克朗计算增长17%（以CER计算增长13%）。

● Sales in North America Operations increased by 35% in Danish kroner (21% at CER), and sales in International Operations increased by 17% in Danish kroner (13% at CER).

● 糖尿病和肥胖症治疗领域销售以丹麦克朗计算增长29%，至1564亿丹麦克朗（以CER计算增长19%），主要由GLP-1糖尿病治疗领域销售驱动，其以丹麦克朗计算增长56%（以CER计算增长42%）。罕见病领域销售以丹麦克朗计算增长7%（以CER计算增长1%）。

● Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 156.4 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 56% in Danish kroner (42% at CER). Rare disease sales increased by 7% measured in Danish kroner (1% at CER).

● 肥胖症治疗领域销售以丹麦克朗计算增长101%（以CER计算增长84%）。2022年12月，Wegovy^®在美国市场的供货已再次获得保证。

● Obesity care sales grew by 101% in Danish Kroner (84% at CER). All Wegovy^® dose strengths were made available again in the US in December 2022.

● 在研发领域，诺和诺德在NASH领域启动了两项基于siRNA技术平台的1期临床试验。

● Within R&D, Novo Nordisk initiated two phase 1 trials in NASH based on the siRNA technology platform.

● 展望2023年，以 CER 计算的销售和经营利润增长目前均预计为13-19%。以丹麦克朗报告的销售和经营利润增长目前预计将比以 CER 计算的增长率低分别4个和5个百分点。

● For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively. 

● 在将于2023年3月23日举行的年度股东大会上，董事会将提议在2022年期末每股派息8.15丹麦克朗。预计2022年的总股息将为每股12.40丹麦克朗，其中每股4.25丹麦克朗的股息已于2022年8月作为中期股息予以派发。董事会还决定启动一项为期12个月，最多280亿丹麦克朗的新股票回购计划。

● At the Annual General Meeting on 23 March 2023, the Board of Directors will propose a final dividend of DKK 8.15 for 2022 per share. The expected total dividend for 2022 is DKK 12.40 per share, of which DKK 4.25 was paid as interim dividend in August 2022. The Board of Directors has decided to initiate a new 12-month share repurchase programme of up to DKK 28 billion.

诺和诺德全球总裁兼CEO周赋德（Lars Fruergaard Jørgensen）表示：“我们对2022年实现双位数销售增长感到非常满意。增长由用于糖尿病和肥胖症治疗的创新GLP-1类药物所驱动。超过3600万糖尿病患者从我们的治疗产品中获益。我们的战略愿景持续取得进展，在2023年，我们将继续专注于强大的业务运营，扩充并推进公司创新产品管线，并为扩大现有和未来的产品组合的产能进行重点投资。”

Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio."